Use study of tenofovir DF in highly active anti-retroviral therapy

Describe the efficacy and safety of tenofovir. Observational, descriptive study. Data were analyzed for the intention-to-treat sample. The primary efficacy end-point included the proportion of patients with HIV-1 RNA level of 50 copies/ml or less. Secondary efficacy end points was the increase of th...

Full description

Saved in:
Bibliographic Details
Published inAnales de medicina interna (Madrid, Spain : 1984) Vol. 23; no. 12; p. 573
Main Authors Fernández Lisón, L C, Vázquez Domínguez, B, Rodríguez Gómez, F J, Hevia Alonso, A, Pujol de la Llave, E
Format Journal Article
LanguageSpanish
Published Spain 01.12.2006
Subjects
Acquired Immunodeficiency Syndrome - drug therapy
Adenine - analogs & derivatives
Adenine - therapeutic use
Adult
Aged
Anti-HIV Agents - therapeutic use
Antiretroviral Therapy, Highly Active
Female
Humans
Male
Middle Aged
Organophosphonates - therapeutic use
Tenofovir
Online AccessGet full text

Cover

More Information
Summary:Describe the efficacy and safety of tenofovir. Observational, descriptive study. Data were analyzed for the intention-to-treat sample. The primary efficacy end-point included the proportion of patients with HIV-1 RNA level of 50 copies/ml or less. Secondary efficacy end points was the increase of the CD4 cell count at week 48. The primary safety end-point was the number of patients with abnormalities (clinical adverse events and laboratory toxicities). The causality of the adverse effects was measured by the Naranjo algorithm. 154 subjects were enrolled; 12 were excluded from all analyses. Efficacy end points: Plasma HIV-1 RNA response: -1.29 +/- 0.97 log10 copies/ml; Patients with HIV-1 RNA levels of 50 copies/ml or less: 28.16%; CD4 cell count response: 40.27 +/- 141.50 cel/mm3. Safety profile was similar to showed at prescribing information, 3 Fanconi Syndrome were detected. Tenofovir supposes an antiretroviral of high effectiveness in our hospital, with an optimum safety profile.
ISSN:0212-7199